CAR-T Therapies Improve with IsoPlexis’ Cellular Fitness & Potency

Immune Fitness and Potency is Key in Developing the Next Generation of Cell Therapies

Cutting edge technologies are leading to the development of novel therapies and  the number of approved therapies are quickly increasing. The characterization of CAR-T cell product fitness and potency has proven challenging due to the complexity of single cell function and heterogeneity.  The cytokine profile from each single CAR-T cell can influence in vivo outcomes based on multiple studies. As therapies become more complex, the ability to identify which cells secrete which specific cytokines as well as the ability to characterize a cell product for immune fitness and potency has become even more crucial in moving cell therapy treatments forward.

Reveal Highly Multiplexed True Cytokine Secretion at the Single-Cell Level

IsoPlexis continues to expand its revolutionary CAR-T functional profiling applications with the continuing partnership with the National Cancer Institute and $4M NCI SBIR grant IsoPlexis has received this year. The IsoLight system provides unique insights to reveal highly multiplexed, true cytokine secretion from a thousand single cells in parallel and is unlocking uniquely correlative biomarkers of response and revealing mechanism of CAR-T therapies. Conventional bulk assays like ELISA and flow cytometry are only estimates and do not show how T cells functionally and proteomically perform among a heterogeneous system.

Advancing Preclinical Cell Therapy Research and Development with Single-Cell Immune Fitness

IsoPlexis is advancing the earliest and most complex stages of preclinical cell therapy development by characterizing fitness and potency.

  • UCLA: Through IsoPlexis’ characterization, Dr. Antoni Ribas, Director of the Tumor Immunology program at UCLA’s Jonsson Comprehensive Cancer Center, discovered unique immune fitness in mice which helped identify lead candidates for combination agonists and adoptive cell therapies.
  • UCSD: Dr. Dan Kaufman presented data on the increase of polyfunctionality and polyfunctional strength index in CRISPR-edited NK cells, which associated with improved anti-tumor activity in iPSC derived NK cells (Figure).
    • This study highlights the functional differences within subtle gene edits that remain hidden when using legacy technologies such as flow-based systems and bulk ELISA.
  • PACT pharma: Novel neoepitope specific adoptive cell therapies were characterized for polyfunctional immune activation
    • Single cell secretion analysis demonstrates that NeoTCR-P1 cells are highly polyfunctional
    • Autologous ex vivo engineered neoepitope specific T cells show the potential to provide significant clinical benefit in solid tumor patients

In a roundtable, leaders in the cell and engineering space (Memorial Sloan Kettering Cancer Center, Moffitt Cancer Center, Washington University at St. Louis, Yale, and UPenn) discuss quality and polyfunctionality on IsoPlexis systems in cell therapy development.

These correlative insights have helped institutions to accelerate their immunotherapy programs. Contact us for a discussion of how to design your next study on functional single cell proteomics. We would love to hear from you.

Share This Article
Be in the Know.
Subscribe to the IsoPlexis Blog
Join 10,000+ top scientists and receive industry pioneers' backed data straight to your inbox.
Your data is in safe hands! We'll never share or sell your data to any third parties, and you may unsubscribe at any time.